We are excited to announce that TAE Life Sciences will have a significant presence at the 20th
International Congress on Neutron Capture Therapy (ICNCT), taking place in Krakow, Poland, from June
24 to 28, 2024.
Anthony
TAE Life Sciences Appoints Commercial Leadership Team and Announces Distribution Deal with Radiosurgery Global
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India).
Dr. Deepak “Dee” Khuntia Joins TAE Life Sciences’ Board of Directors
We are thrilled to announce the addition of Dr. Deepak “Dee” Khuntia, M.D., FASTRO, to the esteemed Board of Directors at TAE Life Sciences. Dr. Khuntia’s vast expertise in radiation oncology and his significant contributions to advancing cancer treatment technologies significantly reinforce our company’s dedication to pioneering advancements in the field.
TAE Life Sciences’ Neutron Beam System Receives Acceptance Enabling the Start of BNCT Clinical Trials in China
TAE Life Sciences, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption.
TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
The Promise of Biologically Targeted Brain Cancer Treatment
How BNCT will improve outcomes for the most difficult-to-treat cancers
TAE Life Sciences Earns Oncology Innovation of the Year Award
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
Study Published in the Journal of Medicinal Chemistry Shows TAE Life Sciences’ BTS Drug Offers Many Advantages Over BPA for BNCT Use
The team at TAE Life Sciences is thrilled to unveil groundbreaking research that could transform the landscape of cancer care. A recent study, focusing on TAE Life Sciences’ Boronotyrosine (BTS) drug, a novel borylated amino acid analogue, has demonstrated exceptional potential to elevate the effectiveness of BNCT in combating cancer.
TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year’s annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Have questions about BNCT? Get answers on our new BNCT Forum